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Pharmacokinetics of Once-Daily Amikacin in Healthy Foals and
Therapeutic Drug Monitoring in Hospitalized Equine Neonates
Erica Paige Bucki, Steeve Giguère, Margo Macpherson, and Rachel Davis
The objectives of this study were to investigate the pharmacokinetics of once-daily amikacin in healthy neonates, to determine
amikacin concentrations in hospitalized foals, and to determine the minimum inhibitory concentrations (MICs) of amikacin against
gram-negative isolates from blood cultures in septic foals. Median half-life, clearance, and volume of distribution of amikacin in
healthy 2- to 3-day-old foals after administration of an intravenous bolus of amikacin (25 mg/kg) were 5.07 hours (4.86–5.45
hours), 1.82 mL/min/kg (1.35–1.97 mL/min/kg), and 0.785 L/kg (0.638–0.862 L/kg), respectively. Statistically significant (P ,.05)
decreases in area under the curve (14% decrease), mean residence time (19% decrease), and C24h plasma amikacin concentrations
(29% decrease) occurred between days 2–3 and 10–11. Plasma amikacin concentrations in healthy foals at 0.5 hours (C0.5h) were
significantly higher (P 5 .02) than those of hospitalized foals. Sepsis, prematurity, and hypoxemia did not alter amikacin concentrations. The MIC at which 90% of all gram-negative isolates from equine neonatal blood cultures were inhibited by amikacin was
4 mg/mL, suggesting that amikacin C0.5h of 40 mg/mL should be targeted to achieve a maximum serum concentration to MIC ratio
of 10:1. The proportion of foals with C0.5h $40 mg/mL was significantly higher (P ,.0001) in hospitalized foals receiving a dose
of amikacin at 25 mg/kg (22/24 or 92%) than in foals receiving a dose at 21 mg/kg (9/25 or 36%), whereas no difference was
found in the proportion of foals with C24h concentrations $3 mg/mL between the 2 groups. An initial dose at 25 mg/kg is
recommended for once-daily amikacin in equine neonates.
Key words: Aminoglycoside; Antimicrobial; Foals; Minimum inhibitory concentration; Sepsis.

S

epsis is the leading cause of morbidity and mortality in
neonatal foals.1,2 Infection of the foal can occur
through several routes, including the placenta in utero, the
respiratory tract, the gastrointestinal tract, or the umbilical
stump. Gram-negative bacteria account for 70–95% of the
microorganisms isolated from blood cultures, with Escherichia coli being the most common isolate.2,3 Other members of the Enterobacteriaceae (Klebsiella spp., Salmonella
spp., and Enterobacter spp.), nonenteric gram-negative rods
(Pasteurella spp. and Actinobacillus spp.), and, less commonly, gram-positive cocci (b-hemolytic steptococci,
Staphylococcus spp., and Enterococcus spp.) also may be
isolated from sick neonatal foals.1–3
Antimicrobial agents provide the basis of therapy for septic foals. Broad-spectrum antimicrobial agents for systemic
administration are usually selected until culture and in vitro
susceptibility results are available. Given that enteric gramnegative microorganisms predominate in neonatal sepsis,
aminoglycosides such as gentamicin or amikacin are commonly used in conjunction with either penicillin or ampicillin for the control of gram-positive bacteria.4,5 Of all aminoglycosides, amikacin is considered the agent of choice
for the treatment of sepsis in equine neonates because of
its lower frequency of resistance among gram-negative isolates obtained from blood cultures.2,4
Aminoglycosides exert concentration-dependent bacterial
killing characteristics. Their rate of killing increases as the
drug concentration increases above the minimum inhibitory
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concentration (MIC) for a given pathogen, with an optimal
maximum serum concentration (Cmax) to MIC ratio of 8–
12:1.6,7 Higher Cmax values also result in a longer postantibiotic effect and decrease selection of resistant bacterial
mutants within a population.8,9 Traditionally, amikacin has
been administered to foals every 8–12 hours.10–13 However,
the considerations described above and examination of data
from other species showing that nephrotoxicity may be
minimized by giving larger doses less frequently, suggest
that optimal dosing of aminoglycosides involves administration of high doses with long dosing intervals.14,15
Although multiple studies report the pharmacokinetics of
multiple daily dosing of amikacin, no information is available on the disposition of once-daily amikacin in a large
population of critically ill equine neonates.10–13 A few studies have determined in vitro susceptibility of bacterial isolates from equine neonatal blood cultures by using the disk
diffusion method but, to the authors’ knowledge, MICs
have never been reported.2,4,5 Knowledge of the MIC of
amikacin against common gram-negative isolates from septic foals would be important to determine targeted amikacin
concentrations in hospitalized patients. Therefore, the objectives of this study were to investigate the pharmacokinetics of once-daily amikacin in clinically healthy neonates,
to determine amikacin concentrations in hospitalized foals
with various illnesses, and to determine the MICs of amikacin against gram-negative isolates obtained from blood
cultures in septic foals.

Materials and Methods
Healthy Equine Neonates
Five mixed-breed pony foals (3 males and 2 females) were studied.
Transfer of passive immunity was confirmed before initiation of the
study by measurement of plasma immunoglobulin G concentration
with a commercial immunoassay.a Foals were considered healthy on
the basis of history, physical examination, CBC, measurement of plasma fibrinogen concentration, and plasma biochemical profile performed the day before administration of amikacin. The foals were kept
with their dams at all times. They were kept at pasture between ex-
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periments and in individual stalls during the experiments with ad libitum access to grass hay and water. Each foal received a single bolus
of amikacin at 2–3 days of age and again at 10–11 days of age. Amikacin sulfateb (250 mg/mL) was administered at a dosage of 25 mg/
kg in a jugular vein. Blood samples were obtained from a catheter
placed in the opposite jugular vein at 0 (before administration), 5, 10,
20, 30, and 45 minutes and at 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24
hours after the foals were dosed. Heparinized blood samples were
centrifuged at 2,800 3 g for 10 minutes. Plasma was collected and
kept frozen at 2708C until assayed.

Hospitalized Foal Population
Case records of all the foals less than 16 days of age admitted to
the veterinary medical teaching hospital at the University of Florida
between January 2000 and June 2003 were examined. Foals were included in the study only if they were treated with once-daily amikacin,
0.5-hour and 24-hour amikacin concentrations were measured at least
once during hospitalization, and an exact body weight was available
for accurate determination of the dose of amikacin administered. Information obtained from the medical records included length of gestation, primary and secondary diagnoses, outcome, sepsis score on
admission,16 arterial partial pressure of oxygen (PaO2) on admission,
blood culture results, age and body weight at time of measurement of
amikacin concentrations, dose of amikacin, number of days of amikacin therapy, and plasma creatinine and blood urea nitrogen (BUN)
concentrations throughout hospitalization. The dosage of amikacin administered was calculated retrospectively by dividing the number of
milligrams of amikacin given just before sample collection by the most
recent body weight. Amikacin sulfateb was administered as a bolus in
a catheter placed in a jugular vein. Blood samples were collected in
heparinized tubes from the opposite jugular or from a cephalic vein
for determination of plama amikacin concentrations 0.5 hours (C0.5h)
and 24 hours (C24h) after the foals were dosed. Heparinized blood
samples were centrifuged at 2,800 3 g for 10 minutes. Plasma samples
obtained outside regular working hours were frozen at 2208C and
analyzed the next working day.
Hospitalized foals were assigned retrospectively to one or more of
the following groups. Foals were considered premature if they were
born at a gestational age # 320 days and displayed immature physical
characteristics. Foals were considered hypoxemic if they had a PaO2
# 65 mm Hg. Foals were considered septic if they had a positive
blood culture or had a sepsis score of 11 or higher. Foals not meeting
any of these criteria were classified as other. Evidence of nephrotoxicity was defined as a 25% increase in plasma creatinine concentration
compared to baseline value or creatinine concentration $ 2 mg/dL in
a foal with a plasma creatinine concentration previously within the
reference range.

Measurement of Amikacin Concentrations
Amikacin concentrations were measured by using a fluorescence
polarization immunoassay on an automated chemistry analyzer.c In
preliminary experiments, known amounts of purified amikacin standard was added to equine plasma at concentrations ranging from 128
to 0.25 mg/mL. Measured concentrations were similar to expected concentrations. Plots of measured concentrations versus expected amikacin concentrations were linear between 1.0 and 128 mg/mL, with a
correlation coefficient (r) of 0.999. The sensitivity of the assay, defined
as the lowest measurable amikacin concentration in equine plasma that
could be distinguished from 0 with 95% confidence, was 0.8 mg/mL.
The interassay coefficient of variation in equine plasma was ,5% at
concentrations of 2–128 mg/mL and #10% at concentrations of 0.8–
1 mg/mL. Low (5.0 mg/mL) and high (30 mg/mL) concentration standards were measured with each sample. Results were only considered
valid if the low concentration standard ranged between 4.25 and 5.75
mg/mL and the high concentration standard ranged between 27.0 and
33.0 mg/mL.
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Pharmacokinetic Analysis
For each healthy foal, 1-, 2-, and 3-compartment models were fit to
serum concentration versus time data by using a pharmacokinetics
computer program.d A 2-compartment model was most appropriate
based on computer-assisted examination of residual plots:
Ct 5 A·e2a·t 1 B·e2b·t,
where Ct is the serum drug concentration at time t; e is the base of
the Naperian logarithm; A and a are the intercept and slope, respectively, of the distribution phase; and B and b are the intercept and
slope, respectively, of the elimination phase. Elimination half-life (t½b)
was calculated as the natural logarithm of 2 divided by b. Pharmacokinetic values were calculated as reported by Gibaldi and Perrier.17
The area under the concentration-time curve (AUC) and the area under
the 1st moment of the concentration-time curve (AUMC) were calculated by using the trapezoidal rule, with extrapolation to infinity,
with C24/b, where C24 was the plasma amikacin concentration at the
final time point (24 hours). Mean residence time (MRT) was calculated
as AUMC/AUC. Apparent volume of distribution based on the AUC
(Vdarea) was calculated as dose/AUC·b and clearance (CL) was calculated from dose/AUC.

MIC of Amikacin against Gram-Negative Isolates
Ninety-four gram-negative bacterial isolates from equine neonatal
blood cultures submitted to the microbiology laboratory of the University of Florida Veterinary Medical Teaching Hospital from January
1998 and March 2003 were examined. Isolates included E coli (n 5
50), Pasteurella spp. (n 5 15), Enterobacter spp. (n 5 11), Klebsiella
spp. (n 5 10), Salmonella enterica subspecies enterica (n 5 6), and
Actinobacillus spp. (n 5 2). Before testing, isolates were subcultured,
checked for purity, and identified by standard identification procedures. The MICs were determined by using microtitration strips.e MICs
obtained by use of this technique have previously been shown to correlate closely with those of the standard broth dilution method.18,19
Concentrations of amikacin tested were 2, 4, 8, and 16 mg/mL. Fresh
isolates were grown on blood agar plates and colonies were suspended
in sterile water to a turbidity equal to that of a 0.5 McFarland standard.
Ten microliters of the suspension were used to inoculate 10 mL of
Mueller Hinton broth for a final bacterial concentration of 1 3 105
colony-forming units/mL. Each well was then inoculated with 50 mL
of bacterial suspension. Strips were sealed and incubated for 18–24
hours at 378C. A test was considered valid only if adequate growth
occurred in control wells. Control strains used to validate the assay at
monthly intervals included Staphylococcus aureus American Type
Culture Collection (ATCC) 29213, Enterococcus faecalis ATCC
29212, Pseudomonas aeruginosa ATCC 27853, E coli ATCC 25922,
and E coli ATCC 35218. In all instances, MICs obtained with the
control stains were within the reference range proposed by the National Committee for Clinical Laboratory Standards.20,21

Statistical Analysis
Differences in C0.5h, C24h, and pharmacokinetic parameters between
clinically healthy 2- to 3-day-old foals and the same foals at 10–11
days of age were assessed with a paired t-test. Data are reported as
median and range.
Differences in C0.5h and C24h concentrations between groups of foals
(normal, premature, hypoxemic, septic, or other) were determined by
analysis of variance. Normality and equal variance of the data were
confirmed in preliminary analysis. Age at time of administration of amikacin and dose were included in the model as covariates. When indicated, multiple pairwise comparisons were done with a Student-Newman-Keuls test. In preliminary analysis, no significant differences were
found in values of C0.5h and C24h concentrations between foals considered
septic based on a positive blood culture versus foals with a negative
blood culture and a septic score of 11 or more. Therefore, the data were
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Table 1. Pharmacokinetic variables (median and range) in 5 foals given a single intravenous dose of amikacin (at a
dosage of 25 mg/kg) at 2–3 days of age and again at 10–11 days of age.
Age, days
Variable

2–3

A, mg/mL
a, 1/h
t1/2a, h
B, mg/mL
b, 1/h
t1/2b, h
Vdarea, L/kg
CL, mL/min/kg
AUC, mg·h/mL
AUMC, mg·h2/mL
MRT, h
C0.5h, mg/mL
C24h, mg/mL

62.6
1.22
0.566
24.9
0.137
5.07
0.785
1.82
228
1,380
6.17
53.0
1.20

(49.8–71.4)
(0.970–2.52)
(0.275–0.715)
(20.6–36.2)
(0.127–0.143)
(4.86–5.45)
(0.638–0.862)
(1.35–1.97)
(215–308)
(1,151–2,221)
(5.34–7.21)
(46–59.9)
(0.90–2.00)

10–11
77.5
1.62
0.429
17.9
0.133
5.20
1.05
2.13
195
841
4.99
58.4
0.85

(68.3–87.3)
(0.899–2.18)
(0.318–0.771)
(11.3–35.6)
(0.120–0.205)
(3.38–5.76)
(0.587–1.22)
(1.45–2.68)
(1.55–288)
(745–1,821)
(4.05–6.33)
(43.8–61)
(,0.80–1.6)

P-value
0.002
0.93
0.89
0.40
0.55
0.70
0.31
0.06
0.03
0.004
0.004
0.38
0.04

A and a, intercept and slope, respectively, of distribution phase; t1/2a, distribution half-life; B and b, intercept and slope, respectively, of
elimination phase; t1/2b, elimination half-life; Vdarea, volume of distribution based on AUC; CL, clearance; AUC, area under the concentrationtime curve; AUMC, area under the first moment of the concentration-time curve; MRT, mean residence time; C0.5h, amikacin concentration 0.5
h after administration; C24h, amikacin concentration 24 h after administration.

combined under a single group designated septic foals. Pearson product
moment correlations were used to determine the relationship between
C0.5h or C24h amikacin concentrations in hospitalized foals and creatinine
concentration or BUN concentration. Logistic regression was used to
examine the relationship between outcome (death or euthanasia versus
discharge from the hospital) and amikacin C0.5h. Differences in proportions were assessed with a Fisher exact test. All analyses were done with
a statistical software.f For all comparisons, values of P , .05 were
considered significant.

Results
Pharmacokinetics of Amikacin in Clinically
Healthy Foals
Concentrations of amikacin 5 minutes after administration of an IV bolus were 89.5 mg/mL (81.0–97.9 mg/mL)
and 100.1 mg/mL (96.2–141.9 mg/mL) for 2- to 3- and 10to 11-day-old foals, respectively. The C24h concentrations
were #2.0 mg/mL for all foals on both days. A statistically
significant decrease occurred in AUC, AUMC, MRT, and
C24h between days 2–3 and 10–11 (Table 1). A tendency (P
5 .06) toward an increase in CL occurred between days 2–
3 and 10–11 (Table 1).

Therapeutic Drug Monitoring in Hospitalized Foals
Forty-nine foals met the criteria for inclusion in the
study. The median age at time of measurement of amikacin
C0.5h and C24h concentrations was 3 days (range 1–15 days).
The median duration of amikacin therapy was 6 days (range
3–23 days). The median dosage of amikacin administered
was 23.5 mg/kg (range 16.7–28.0 mg/kg). The proportion
of foals with C0.5h $ 40 mg/mL was significantly higher in
foals receiving a dose at .23.5 mg/kg (median dosage: 25
mg/kg; 22/24 or 92%) than in foals receiving a dose at
,23.5 mg/kg (median dosage 21 mg/kg; 9/25 or 36%; P
,.0001). Seven (14%) of 49 hospitalized foals had C24h
lower than the limit of sensitivity of the assay. The C24h
amikacin concentrations were ,2 mg/mL in 37 foals, 2–3

mg/mL in 7 foals, 3–4 mg/mL in 3 foals, and $4 mg/mL
in 2 foals (5.0 and 9.0 mg/mL). No difference was found
in the proportion of foals with C24h $3 mg/mL between
foals that received a dose of amikacin at .23.5 mg/kg (3/
24 or 13%) versus foals that received a dose at ,23.5 mg/
kg (2/25 or 8%; P 5 .67).
Forty-two (86%) of 49 foals were discharged from the
hospital and 7 (14%) foals died (n 5 1) or were euthanized
(n 5 6). Reasons for death or euthanasia included septic
arthritis (n 5 4), prematurity (n 5 1), hypoxic ischemic
encephalopathy (n 5 1), and sepsis (n 5 1). Gram-negative
bacteria (Klebsiella spp.) were isolated from only 1 of the
nonsurvivors. No correlation was found between C0.5h or
C24h amikacin concentrations and creatinine or BUN concentrations. No association was found between C0.5h and
survival. Plasma creatinine concentrations were monitored
during the course of amikacin therapy in 40 foals. Two
(5%) of 40 foals developed evidence of nephrotoxicity.
Eight hospitalized foals were classified as premature, 10
were hypoxemic, 28 were septic, and 19 did not fall within
any of these categories and were classified as other (Table
2). Most of the foals classified as other were diagnosed with
hypoxic-ischemic encephalopathy, failure of transfer of passive immunity, or mild diarrhea. Clinically healthy foals
had significantly higher C0.5h than all groups of hospitalized
foals (Table 2). C0.5h and C24h amikacin concentrations were
not significantly different between groups of hospitalized
foals (Table 2).

MIC of Amikacin against Gram-Negative Isolates
from Equine Neonatal Blood Cultures
The MICs of amikacin inhibiting at least 90% of E coli,
Pasteurella spp., Enterobacter spp., and Klebsiella spp. isolates (MIC90) were 4, 4, #2, and #2 mg/mL, respectively
(Table 3). The MIC90 for all gram-negative isolates combined was 4 mg/mL.
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Table 2. Amikacin concentrations 0.5 hours (C0.5h) and
24 h (C24h) after administration (median and range) in
healthy and hospitalized foals treated with amikacin intravenously at a dosage ranging between 16.7 and 28.0 mg/
kg, once daily.
Amikacin concentration, mg/mL
Group
Normal (n 5 5)
Premature (n 5 8)
Hypoxemic (n 5 10)
Septic (n 5 28)
Other (n 5 19)

C0.5hs
54.5a
40.5b
45.5b
41.3b
40.0b

(43.8–61.0)
(32.9–47.4)
(32.9–63.0)
(29.4–63.0)
(20.2–61.1)

C24h
0.9
1.4
1.3
1.5
1.4

(,0.8–2.0)
(,0.8–9.0)
(0.8–9.0)
(,0.8–9.0)
(,0.8–4.0)

a,b
Different letters in a column indicate a statistically significant difference between groups (P , .05).

Discussion
The combination of an aminoglycoside with a beta-lactam antimicrobial agent has been the mainstay of therapy
for septic foals.5 Studies in humans and laboratory animals
have shown that a once-daily administration of aminoglycosides is more effective, decreases the emergence of resistant isolates, and results in similar or less nephrotoxicity
than multiple daily dosing.22,23 Such a dosing scheme has
been investigated with gentamicin in adult horses with no
evidence of nephrotoxicity.24 In a recent study, once-daily
amikacin was administered to 7 healthy equine neonates at
a dosage of 21 mg/kg for 10 days with no apparent nephrotoxicity.25 In the same study, significant age-related
changes in pharmacokinetics included a decrease in t1/2b,
AUC, and MRT, as well as an increase in clearance between
day 1 and day 10.25 In the present study with a higher
dosage (25 mg/kg), significant decreases in AUC, AUMC,
MRT, and C24h between days 2–3 and 10–11 were observed,
whereas CL tended to increase (Table 2). Values for t1/2b
(5.2 hours) and Vd (1.05 L/kg) in 10-day-old foals in the
present study were slightly higher than those previously
reported in foals of the same age (3.85 hours and 0.671 L/
kg, respectively), whereas the CL was similar between the
2 studies.25
Therapeutic drug monitoring should be performed when
administering aminoglycosides to minimize the risk of
nephrotoxicity and allow individualized adjustment of dose
or dosing interval. In one study, human patients treated with
multiple daily dosing aminoglycoside monitored by a pharmacokinetic service had shorter hospital stays, shorter duration of therapy, increased antibiotic efficacy, and a 13.4%
lower incidence of nephrotoxicity compared to patients who
were not subjected to guided therapeutic drug monitoring.26
However, the issue of optimal plasma concentration and
timing for sample collection after once-daily aminoglycoside administration remains controversial and no established method has found universal acceptance.22 A Cmax is
obtained after a predetermined distribution period and is
considered representative of maximal tissue concentration.22,27 In most studies, Cmax has been obtained 0.5–1 hours
after IV bolus administration.10,27,28 Although some studies
recommend collection of a 2nd sample just before administering the next dose (trough), others recommend a mid-
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Table 3. Minimum inhibitory concentrations (MICs) of
amikacin against 94 gram-negative bacterial isolates obtained from blood culture in equine neonates.
MIC, mg/mL
Microorganism

90%

50%

Range

Escherichia coli (n 5 50)
Pasteurella spp. (n 5 15)
Enterobacter spp. (n 5 11)
Klebsiella spp. (n 5 10)
Salmonella enterica (n 5 6)
Actinobacillus spp. (n 5 2)
All isolates combined (n 5 94)

4
4
#2
#2
—
—
4

#2
4
#2
#2
4
—
#2

#2–8
#2–8
#2
#2
#2–8
4–8
#2–8

point sample, typically 6–14 hours after administration.22,27,29,30 Based on our results, collection of a Cmax sample at 0.5 hours would appear too early to estimate the
elimination phase of the disposition curve. In addition, collection of the 2nd sample at 24 hours resulted in undetectable amikacin concentrations in 7 (14%) of 49 foals. For
these reasons, pharmacokinetic variables could not be calculated accurately from hospitalized foals in the present
study. Based on our data, the 1st sample should be taken
1.5–2 hours after administration to obtain a sample in the
1st part of the elimination phase of the drug. The 2nd sample should be taken 8–16 hours after drug administration to
ensure measurable drug concentrations.
Knowledge of trough amikacin concentration may be of
particular importance in therapeutic drug monitoring because trough aminoglycoside concentration has been shown
to be a significant factor for development of nephrotoxicity.31 Optimal trough concentration for minimizing nephrotoxicity after administration of once-daily amikacin in humans is controversial, with recommendations ranging from
,1 mg/mL to ,10 mg/mL.32–35 The present study failed to
identify a correlation between C24h amikacin concentration
and serum creatinine concentrations or development of
nephrotoxicity in hospitalized foals. This may be due to the
fact that therapeutic drug monitoring was done early during
amikacin therapy. Dose, dosing interval, or both were adjusted in all foals with C24h concentration .3 mg/mL, thereby preventing accurate assessment of the effect of longterm high C24h concentration on development of nephrotoxicity. In the present study, 2 (5%) of 40 foals in which
plasma creatinine concentrations were monitored during
amikacin therapy developed renal dysfunction, as evidenced by an increase in creatinine concentrations above
baseline values and above the reference range for our laboratory. Monitoring serum creatinine concentration is a fairly insensitive mean of determining renal dysfunction because these values do not exceed the reference range until
glomerular filtration has decreased by approximately 75%.
The incidence of nephrotoxicity (also defined by an increase in creatinine concentrations) in humans treated with
once-daily amikacin has ranged between 5 and 21%.32,35
Previous studies using multiple daily dosing of amikacin
have revealed significant alterations of values of various
pharmacokinetic parameters in premature, hypoxemic, and
azotemic foals compared to clinically healthy animals.10–12
In one study also using multiple daily dosing of amikacin,
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sepsis score and serum creatinine concentrations were inversely correlated to amikacin clearance and appeared to be
useful indicators of altered drug disposition.12 In the present
study, all groups of hospitalized equine neonates had significantly lower amikacin C0.5h compared to clinically
healthy foals. However, prematurity, hypoxemia, and sepsis
did not result in significant changes in amikacin C0.5h and
C24h concentrations compared to other hospitalized foals
(Table 2). Similarly, no correlation was found between C0.5h
and C24h amikacin concentrations and creatinine concentrations or BUN concentrations. Although renal dysfunction
would be expected to alter the disposition of amikacin, the
lack of correlation between C0.5h and C24h amikacin concentrations and creatinine concentrations in the present study
is not unexpected for 2 reasons. First, high plasma creatinine concentrations in newborn foals may be the result of
placental dysfunction and do not necessarily represent abnormal glomerular filtration.36 In addition, it is general practice in our hospital to use a 3rd-generation cephalosporin
instead of amikacin in foals with high BUN or creatinine
concentrations.
Multiple in vivo and in vitro studies have shown that the
rate of bacterial killing with aminoglycosides increases as
the drug concentration increases above the MIC for a given
pathogen with an optimal Cmax to MIC ratio of approximately 8–12:1.6–8,37 In addition, a Cmax to MIC ratio of at
least 10:1 may prevent the emergence of resistant pathogens.8,9 A few studies have reported in vitro susceptibility
of bacterial isolates from equine neonatal blood cultures.2,4,5
Bacterial isolates with an MIC # 16 mg/mL are considered
to be susceptible to amikacin.21 Maintaining a Cmax to MIC
ratio of 10:1 for all susceptible isolates would imply achieving C0.5h of 160 mg/mL. Based on data presented in Table
2, this approach would be impossible. It was therefore necessary to know the true MIC of amikacin against gramnegative isolates from blood cultures to make appropriate
recommendations for targeted amikacin Cmax in neonatal
foals. The MIC at which at least 90% of all gram-negative
isolates were inhibited by amikacin was 4 mg/mL, suggesting that amikacin C0.5h of 40 mg/mL should be targeted
(Table 3). The proportion of foals with C0.5h $ 40 mg/mL
was significantly higher in foals receiving a dose at approximately 25 mg/kg (22/24 or 92%) than in foals receiving a dose at approximately 21 mg/kg (9/25 or 36%),
whereas no difference was found in the proportion of foals
with C24h concentrations $ 3 mg/mL between the 2 groups.
The lack of association between C0.5h and survival in the
present study may have been due to the small number of
nonsurvivors and to the fact that many foals included in
the study did not have confirmed bacterial infections.
In conclusion, the results of this study show that age
affects the pharmacokinetics of once-daily amikacin in neonatal foals. Hospitalized foals have lower amikacin C0.5h
than healthy foals. Sepsis, prematurity, and hypoxemia did
not alter C0.5h and C24h amikacin concentrations after oncedaily administration to hospitalized foals. An initial dose at
25 mg/kg is recommended to optimize the Cmax to MIC
ratio. This dose resulted in adequate C0.5h and C24h concentrations in most, but not all, foals. Therefore, therapeutic
drug monitoring to allow individual adjustment of dose and

dosing interval is strongly recommended in equine neonatal
patients.
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f
SPSS 12.0, SPSS Inc, Chicago, IL
a

b
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